Clinical Trial Update: Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of allogeneic stem cell transplant with ATG, high-dose melphalan, and fludarabine in breast cancer was terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Allogeneic stem cell transplant with ATG, high-dose melphalan, and fludarabine

Snippet

Sponsor: University of California, San Diego | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-11-24